Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22694097 | 0.88 | PTPN11 (0.46) | PTPN11 | |
| SCHEMBL22694096 | 0.88 | PTPN11 (0.59) | PTPN11 | |
| SCHEMBL21154727 | 0.88 | PTPN11 (0.59) | PTPN11 | |
| SCHEMBL19785304 | 0.86 | PTPN11 (0.51) | PTPN11 | |
| SCHEMBL21154444 | 0.86 | PTPN11 (0.58) | PTPN11 | |
| SCHEMBL21115050 | 0.79 | PTPN11 (0.57) | PTPN11 | |
| SCHEMBL21115049 | 0.79 | PTPN11 (0.57) | PTPN11 | |
| SCHEMBL23186853 | 0.79 | PTPN11 (0.71) | PTPN11 | |
| SCHEMBL24075956 | 0.78 | PTPN11 (0.61) | PTPN11 | |
| SCHEMBL19785462 | 0.78 | PTPN11 (0.59) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | PTPN18, PTPN7, PTPN1 | PTPN11 14/4885SCN10A 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.